美国OTC市场Navidea Biopharmaceuticals, Inc.（NAVB.us）股价拉升900.00% 市值涨900.9万美元

自选股智能写手07-15

北京时间2024年07月15日23时26分，美国OTC市场Navidea Biopharmaceuticals, Inc.（NAVB.us）股票出现异动，股价大幅拉升900.00%。截至发稿，该股报0.010美元/股，成交量5229股，换手率0.01%，振幅900.00%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-2.26百万美元，每股收益-0.02美元，毛利-36030.00美元...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2451624910?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-15 23:26","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2451624910","market":"us","top_or_hot":-1,"title":"美国OTC市场Navidea Biopharmaceuticals, Inc.（NAVB.us）股价拉升900.00% 市值涨900.9万美元","media":"自选股智能写手","content":"<div>\n<p>北京时间2024年07月15日23时26分，美国OTC市场Navidea Biopharmaceuticals, Inc.（NAVB.us）股票出现异动，股价大幅拉升900.00%。截至发稿，该股报0.010美元/股，成交量5229股，换手率0.01%，振幅900.00%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-2.26百万美元，每股收益-0.02美元，毛利-36030.00美元...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071523260195c12693&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美国OTC市场Navidea Biopharmaceuticals, Inc.（NAVB.us）股价拉升900.00% 市值涨900.9万美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美国OTC市场Navidea Biopharmaceuticals, Inc.（NAVB.us）股价拉升900.00% 市值涨900.9万美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-15 23:26 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071523260195c12693&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>北京时间2024年07月15日23时26分，美国OTC市场Navidea Biopharmaceuticals, Inc.（NAVB.us）股票出现异动，股价大幅拉升900.00%。截至发稿，该股报0.010美元/股，成交量5229股，换手率0.01%，振幅900.00%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-2.26百万美元，每股收益-0.02美元，毛利-36030.00美元...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071523260195c12693&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NAVB","symbol_name":"Navidea生物制药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071523260195c12693&s=b","article_id":"2451624910","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071523260195c12693&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2451624910","pubTimestamp":1721057161,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"北京时间2024年07月15日23时26分，美国OTC市场Navidea Biopharmaceuticals, Inc.股票出现异动，股价大幅拉升900.00%。截至发稿，该股报0.010美元/股，成交量5229股，换手率0.01%，振幅900.00%。美国OTC市场Navidea Biopharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.14%。美国OTC市场Navidea Biopharmaceuticals, Inc.公司简介：Navidea Biopharmaceuticals Inc是一家专注于精准医学的生物技术公司。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"NAVB":"Navidea生物制药","BK4139":"生物科技"},"translate_title":"The stock price of Navidea Biopharmaceuticals, Inc. (NAVB.us) in the U.S. OTC market rose 900.00% and its market value rose by $9.009 million","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NAVB":0.9},"content_text":"北京时间2024年07月15日23时26分，美国OTC市场Navidea Biopharmaceuticals, Inc.（NAVB.us）股票出现异动，股价大幅拉升900.00%。截至发稿，该股报0.010美元/股，成交量5229股，换手率0.01%，振幅900.00%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-2.26百万美元，每股收益-0.02美元，毛利-36030.00美元，市盈率-0.12倍。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。美国OTC市场Navidea Biopharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.14%。其相关个股中，Aeon Biopharma, Inc.、Protagenic Therapeutics Inc C/Wts 29/04/2026 (To Pur Com)、Psyence Biomedical Ltd C/Wts 25/01/2029(To Pur Com)涨幅较大，Scinai Immunotherapeutics Ltd、Artelo Biosciences, Inc.、Qualigen Therapeutics, Inc.较为活跃，换手率分别为3158.77%、114.50%、110.34%，振幅较大的相关个股有Aeon Biopharma, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029(To Pur Com)、Scinai Immunotherapeutics Ltd，振幅分别为150.36%、74.53%、71.27%。美国OTC市场Navidea Biopharmaceuticals, Inc.公司简介：Navidea Biopharmaceuticals Inc是一家专注于精准医学的生物技术公司。 其产品，精密免疫诊断剂和免疫治疗产品旨在帮助识别未发现的疾病并改善靶向治疗。 该公司的平台称为Manocept技术，旨在开发针对癌症，自身免疫性疾病和其他炎症性疾病的下一代靶向诊断和疗法。公司的产品之一是Lymphoseek，一种可定位淋巴结的放射性诊断剂。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2451624910"}